Shareholders Approve Abbott Merger Agreement, Reject Executive Compensation

summarizeSummary

Exact Sciences' stockholders approved the merger agreement with Abbott Laboratories, advancing the acquisition, but rejected the advisory proposal on executive compensation related to the deal.

check_boxKey Events · M&A and Partnerships · EXAS

• Merger Agreement Approved

  Stockholders overwhelmingly voted to adopt the Agreement and Plan of Merger with Abbott Laboratories, with 128,431,562 votes For and 386,941 Against.

• Executive Compensation Rejected

  Shareholders voted against the advisory proposal regarding executive compensation related to the merger, with 85,655,344 votes Against compared to 42,290,727 For.

• Quorum Achieved

  A quorum was established at the Special Meeting with 67.56% of Exact Sciences' common stock outstanding present or represented.

• Regulatory Approvals Pending

  Completion of the merger remains subject to the satisfaction or waiver of customary closing conditions, including the receipt of required regulatory approvals.

auto_awesomeAnalysis · EXAS · Industrial Applications And Services

This 8-K filing confirms a critical step in Exact Sciences' acquisition by Abbott Laboratories, with shareholders overwhelmingly approving the merger agreement. This vote removes a significant contingency and moves the transaction closer to completion, which has been a recurring theme in recent filings, including the 10-K and various proxy materials. The market has been anticipating this merger, and its approval provides greater certainty. However, shareholders notably rejected the advisory proposal on executive compensation tied to the merger, signaling dissatisfaction with the proposed payouts, though this non-binding vote does not impact the merger's progression. Investors should now focus on the remaining regulatory approvals required for the deal to close.